Archives

  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • G007-LK: Precision Tankyrase 1/2 Inhibitor for Wnt/β-Cate...

    2025-12-15

    G007-LK: Precision Tankyrase 1/2 Inhibitor for Wnt/β-Catenin Research

    Understanding the Principle: Tankyrase 1/2 Inhibition in Wnt Signaling and Cancer Biology

    The G007-LK tankyrase 1/2 inhibitor (SKU B5830) is a highly selective, potent small molecule designed to target tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2)—key enzymes in the poly(ADP-ribosyl)ating polymerase family. Tankyrases regulate crucial cellular processes such as Wnt/β-catenin signaling, telomere maintenance, and cell cycle progression. Their enzymatic activity, specifically auto-poly(ADP-ribosyl)ation, facilitates the assembly/disassembly of multiprotein complexes pivotal for cellular homeostasis and oncogenic transformation.

    In cancer biology, tankyrases drive tumorigenesis by destabilizing AXIN1/2 and promoting nuclear accumulation of β-catenin, fueling aberrant transcription and proliferation—especially in APC-mutant colorectal cancer and hepatocellular carcinoma (HCC). By inhibiting tankyrase activity (IC50: 46 nM for TNKS1, 25 nM for TNKS2), G007-LK induces AXIN1/2 stabilization, β-catenin degradation, and suppresses the Wnt/β-catenin pathway. This multifaceted mechanism empowers researchers to interrogate pathway dependencies, optimize combination therapies, and unravel resistance mechanisms in oncology models.

    Step-by-Step Workflow: Optimizing Experimental Setups with G007-LK

    1. Compound Handling and Preparation

    • Storage: Store G007-LK solid at -20°C. Avoid repeated freeze-thaw cycles and long-term storage of dissolved aliquots.
    • Solubility: Achieves ≥26.5 mg/mL in DMSO; insoluble in water and ethanol. For rapid dissolution, warm at 37°C or use an ultrasonic bath.
    • Stock Solutions: Prepare concentrated stocks (e.g., 10 mM) in DMSO. Filter sterilize if desired for cell-based assays.

    2. Cell-Based Assays: Protocol Highlights

    • Cell Line Selection: Use APC-mutant colorectal cancer models (e.g., SW480, COLO-320DM) or Wnt3a-induced HEK 293 cells for pathway interrogation. For Hippo pathway studies, HCC lines such as HepG2 or Huh7 are suitable.
    • Treatment Regimen: Typical working concentrations range from 0.01–10 μM. For Wnt reporter assays, G007-LK potently inhibits ST-Luc with an IC50 of 0.05 μM.
    • Control Conditions: Include DMSO-matched controls and, where relevant, a structurally distinct tankyrase inhibitor (e.g., XAV-939) for comparative analysis.

    3. Readouts and Analytical Endpoints

    • Wnt/β-Catenin Pathway: Quantify cytosolic and nuclear β-catenin by immunoblotting; measure transcriptional activity via TCF/LEF/ST-Luc reporter assays; assess AXIN1/2 stabilization.
    • Hippo Pathway Modulation: Monitor YAP/TAZ protein levels, YAP/TEAD reporter activity, and downstream gene expression. Assess AMOTL1/2 stabilization as a mechanistic readout (Jia et al., 2017).
    • Degradasome Formation: Detect formation of β-catenin/β-TrCP/ubiquitin-positive puncta by high-resolution microscopy, confirming β-catenin degradation induction.
    • Cell Proliferation and Viability: Use MTT, CellTiter-Glo, or colony formation assays to quantify antiproliferative effects.

    Advanced Applications and Comparative Advantages

    1. Dissecting Wnt/β-Catenin and Hippo Crosstalk

    G007-LK uniquely enables mechanistic dissection of Wnt/β-catenin and Hippo signaling interplay. Reference studies show that tankyrase inhibition not only induces β-catenin degradation but also downregulates YAP/TAZ oncogenic activity by stabilizing AMOTL1/2, thereby providing a dual-pronged pathway blockade (Jia et al., 2017). This places G007-LK at the vanguard for modeling tumor suppressor reactivation and investigating resistance to pathway-targeted therapies.

    2. APC Mutation Colorectal Cancer Research

    In APC-mutant colorectal cancer models, G007-LK induces robust formation of dynamic degradasomes and significantly reduces cytosolic and nuclear β-catenin levels, leading to colorectal tumor growth suppression in xenograft models. This capacity, coupled with high selectivity, makes it the specific tankyrase inhibitor for Wnt signaling research—enabling scientists to probe synthetic lethal interactions and test combination regimens.

    3. Combination Therapy Modeling

    G007-LK synergizes with MEK and AKT inhibitors to further suppress proliferation in HCC and colorectal models, as demonstrated in colony formation and viability assays (Jia et al., 2017). This opens new avenues for preclinical evaluation of multi-pathway targeted strategies, overcoming monotherapy resistance.

    4. Comparative Product Landscape

    Compared to first-generation tankyrase inhibitors (e.g., XAV-939), G007-LK offers superior potency, selectivity, and in vivo efficacy, as detailed in this thought-leadership review. Where XAV-939 may exhibit off-target effects and limited solubility, G007-LK’s optimized chemistry ensures reproducibility and greater translational promise—making it an indispensable tankyrase inhibitor for cancer biology.

    5. Application Extension: Hepatocellular Carcinoma

    Expanding beyond colorectal models, G007-LK’s efficacy in HCC underscores its value in studying poly(ADP-ribosyl)ation inhibition and Hippo pathway modulation. As highlighted in the reference study and in this complementary guide, G007-LK suppresses liver cancer cell growth by reducing YAP nuclear localization—extending its relevance to a broader spectrum of solid tumors.

    Troubleshooting and Optimization Tips for Reliable Results

    • Solubility Pitfalls: If precipitation occurs upon dilution, gently warm the solution or vortex in an ultrasonic bath. Always dilute into pre-warmed culture media to minimize precipitation.
    • DMSO Toxicity: Keep final DMSO concentrations ≤0.1% in cell-based assays. Include DMSO-only controls to distinguish cytotoxicity.
    • Batch-to-Batch Consistency: Source G007-LK exclusively from APExBIO to ensure lot-to-lot reliability and analytical purity, as emphasized in this scenario-driven resource.
    • Assay Sensitivity: For reporter or immunoblot assays, titrate G007-LK concentrations to identify the minimal effective dose while avoiding off-target effects.
    • Degradasome Visualization: Use confocal or super-resolution microscopy for optimal detection of β-catenin/β-TrCP/ubiquitin-positive puncta, a hallmark of β-catenin degradation induction.
    • Combination Studies: When modeling pathway cross-talk, stagger drug addition to dissect direct versus indirect effects. Validate pathway inhibition by monitoring both β-catenin and YAP/TAZ endpoints.
    • In Vivo Use: For mouse xenograft studies, formulate G007-LK in DMSO or appropriate vehicles as per published protocols; monitor for compound stability and bioavailability.

    Future Outlook: Expanding the Utility of G007-LK in Cancer Biology

    As the field advances, G007-LK is poised to drive next-generation research in oncogenic pathway mapping, drug resistance, and therapeutic synergy. Its dual inhibition of Wnt/β-catenin and Hippo/YAP signaling—quantified through robust endpoint assays and validated in both colorectal and hepatocellular models—positions it as an essential tool for preclinical discovery and mechanistic interrogation.

    Emerging research is leveraging G007-LK to:

    • Unravel synthetic lethal interactions in APC-mutant backgrounds
    • Model tumor microenvironment feedback and immune modulation
    • Drive biomarker discovery for patient stratification in clinical studies

    The compound’s versatility and proven performance, highlighted in resources like this protocol-driven article, underscore why APExBIO’s G007-LK is the preferred specific tankyrase inhibitor for Wnt signaling research worldwide.

    For detailed specifications and ordering information, visit the G007-LK tankyrase 1/2 inhibitor product page.

    References